Oleuropein Aglycone

Chemical Class	Secoiridoid (deglycosylated oleuropein derivative)
Molecular Formula / CAS	C₁₉H₂₂O₈ · CAS 31773-95-2
Primary Botanical Source(s)	Olea europaea (olive) — formed from oleuropein in ripening fruit and pressed oil
Plant Part	Fruit / pressed oil; formed via enzymatic hydrolysis rather than present at fixed levels in unprocessed leaf
Typical Content	Abundant in extra-virgin olive oil specifically, where enzymatic and mechanical processing during pressing converts leaf-typical oleuropein glycoside into the aglycone form
Solubility / Format	Present within olive fruit and oil matrices; not isolated at commercial ingredient scale
Sourcing Status	Informational-only — a distinct process intermediate, not the compound Herbuno’s oleuropein-standardised products are calibrated to
Buy from Herbuno	Not applicable — see HerbIQ Compound Index for related olive-derived ingredients

Name origin: Oleuropein aglycone takes its name directly from its parent compound, oleuropein — the “aglycone” suffix is standard glycoside chemistry nomenclature denoting the non-sugar portion of a glycoside remaining after the attached sugar group is removed. Traditional use: Oleuropein aglycone has no independent traditional-use history; olive fruit, leaf and oil each carry their own long Mediterranean traditional-medicine and dietary histories, but the aglycone form specifically was not distinguished from its parent glycoside until modern analytical chemistry made the distinction possible. Research trajectory: Research interest in oleuropein aglycone grew substantially once researchers at the University of Florence identified it, rather than oleuropein itself, as the polyphenol responsible for a specific anti-amyloid activity relevant to Alzheimer’s disease research, prompting a still-active line of investigation into its neuroprotective and anti-amyloid mechanisms distinct from oleuropein glycoside research generally. Safety context: Oleuropein aglycone is not a controlled or toxic substance; it is classified informational-only here because it is chemically distinct from the oleuropein glycoside that Herbuno’s standardised olive leaf products are calibrated to, and no dedicated aglycone-standardised olive ingredient currently exists in supply.

---

Evidence for Oleuropein Aglycone Applications

Oleuropein aglycone forms when the glucose molecule is enzymatically cleaved from oleuropein, the dominant secoiridoid glycoside of olive leaf, by β-glucosidase activity that occurs naturally during olive fruit ripening and, more extensively, during oil pressing when crushing the fruit brings endogenous glucosidase enzymes into contact with oleuropein. This makes fresh extra-virgin olive oil — rather than olive leaf, where oleuropein remains predominantly in its intact glycoside form — the richer natural source of the aglycone specifically. Claim strength: Moderate.

The most substantial body of oleuropein aglycone research concerns Alzheimer’s-relevant amyloid pathology. In transgenic TgCRND8 mice overexpressing mutant human amyloid precursor protein, eight weeks of dietary oleuropein aglycone supplementation reduced amyloid-beta plaque deposits and produced measurable improvement in disease-associated markers, with a review of this and related work concluding that oleuropein aglycone shows in-vivo effectiveness against Alzheimer’s-associated pathology in animal models specifically (Casamenti et al. 2015). Claim strength: Moderate.

Mechanistically, oleuropein aglycone has been shown to interfere directly with amyloid-beta self-assembly, redirecting the aggregation process toward non-toxic amyloid assemblies rather than the neurotoxic oligomeric forms implicated in Alzheimer’s pathology, and separately to reduce generation of pyroglutamylated amyloid-beta (pE3-Aβ), a particularly aggregation-prone amyloid variant, while activating neuronal autophagy pathways even in aged transgenic mice at advanced disease stages (Luccarini et al. 2015). This mechanistic specificity is what distinguishes the aglycone research from broader olive-polyphenol antioxidant claims. Claim strength: Moderate.

A dedicated review of oleuropein aglycone in Alzheimer’s disease research describes it as a radical-scavenging, antioxidative secoiridoid compound specifically abundant in extra-virgin olive oil, generated via glucosidase activity released during fruit crushing, and considers it a promising candidate for inhibiting the amyloid oligomer nucleation and growth process implicated in neurodegeneration (et al. 2016). All of this research remains preclinical — conducted in transgenic mouse models and cell culture — and has not been tested in human Alzheimer’s patients. Claim strength: Emerging.

For sourcing purposes, the key distinction formulators must hold is that oleuropein aglycone is chemically and functionally distinct from the oleuropein glycoside that standardised olive leaf extracts — including Herbuno’s Oleuropein 40% and 20% Powder products — are calibrated to. These leaf-derived, glycoside-standardised extracts do not represent a verified source of the aglycone form, since aglycone formation depends on enzymatic hydrolysis conditions present during fruit pressing rather than being an inherent property of standardised leaf extract material. Claim strength: Moderate.

---

Dosage & Formulator Specification

Because no commercially standardised oleuropein aglycone ingredient exists, there is no established human supplemental dosing range for the isolated compound. Published animal research has used dietary supplementation at approximately 50 mg/kg of diet over an eight-week period in a transgenic mouse model, a dose and delivery method that does not translate directly to a human oral supplement without dedicated pharmacokinetic and safety work.

Analytical distinction between oleuropein and its aglycone requires HPLC or LC-MS methods capable of resolving the glycoside from its deglycosylated form, since the two compounds differ in polarity and chromatographic behaviour; a standard oleuropein assay calibrated to the glycoside form will not accurately quantify aglycone content, and vice versa.

In practice, meaningful oleuropein aglycone exposure requires either fresh, unrefined extra-virgin olive oil where natural fruit-crushing enzymatic activity has already generated the aglycone, or a deliberate enzymatic hydrolysis step (using β-glucosidase) applied to an oleuropein-rich leaf extract under controlled conditions — a specialised process step beyond standard extract production and not part of Herbuno’s current production route for any olive product.

Regulatory positioning for oleuropein aglycone follows the same general olive-ingredient food and botanical precedent as oleuropein and hydroxytyrosol, given the shared parent plant; no dedicated aglycone-specific regulatory monograph exists. Because current research is confined to animal models, formulators should avoid extending neuroprotective or Alzheimer’s-related claims to any olive product on the basis of oleuropein aglycone research unless the specific ingredient has verified aglycone content.

---

Frequently Asked Questions — Oleuropein Aglycone

Related compounds: Verbascoside, Hydroxytyrosol